Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Radiotherapie en chirurgie met of zonder pembrolizumab bij stadium III-wekedelensarcoom
feb 2025 | Bot en wekedelentumoren, Immuuntherapie